291 related articles for article (PubMed ID: 32790954)
1. Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma.
Ikeda S; Abe F; Matsuda Y; Kitadate A; Takahashi N; Tagawa H
Cancer Sci; 2020 Nov; 111(11):4088-4101. PubMed ID: 32790954
[TBL] [Abstract][Full Text] [Related]
2. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.
Ikeda S; Tagawa H
Cancer Sci; 2021 Oct; 112(10):3995-4004. PubMed ID: 34310776
[TBL] [Abstract][Full Text] [Related]
3. Dicer mediating the expression of miR-143 and miR-155 regulates hexokinase II associated cellular response to hypoxia.
Yao M; Wang X; Tang Y; Zhang W; Cui B; Liu Q; Xing L
Am J Physiol Lung Cell Mol Physiol; 2014 Dec; 307(11):L829-37. PubMed ID: 25172909
[TBL] [Abstract][Full Text] [Related]
4. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible KDM3A addiction in multiple myeloma.
Ikeda S; Kitadate A; Abe F; Takahashi N; Tagawa H
Blood Adv; 2018 Feb; 2(4):323-334. PubMed ID: 29444873
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.
Martin SK; Diamond P; Williams SA; To LB; Peet DJ; Fujii N; Gronthos S; Harris AL; Zannettino AC
Haematologica; 2010 May; 95(5):776-84. PubMed ID: 20015878
[TBL] [Abstract][Full Text] [Related]
7. An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1
Xu S; Zhou T; Doh HM; Trinh KR; Catapang A; Lee JT; Braas D; Bayley NA; Yamada RE; Vasuthasawat A; Sasine JP; Timmerman JM; Larson SM; Kim Y; MacLeod AR; Morrison SL; Herschman HR
Cancer Res; 2019 May; 79(10):2748-2760. PubMed ID: 30885978
[TBL] [Abstract][Full Text] [Related]
8. Metabolic signature identifies novel targets for drug resistance in multiple myeloma.
Maiso P; Huynh D; Moschetta M; Sacco A; Aljawai Y; Mishima Y; Asara JM; Roccaro AM; Kimmelman AC; Ghobrial IM
Cancer Res; 2015 May; 75(10):2071-82. PubMed ID: 25769724
[TBL] [Abstract][Full Text] [Related]
9. Deregulation of Hexokinase II Is Associated with Glycolysis, Autophagy, and the Epithelial-Mesenchymal Transition in Tongue Squamous Cell Carcinoma under Hypoxia.
Chen G; Zhang Y; Liang J; Li W; Zhu Y; Zhang M; Wang C; Hou J
Biomed Res Int; 2018; 2018():8480762. PubMed ID: 29682563
[TBL] [Abstract][Full Text] [Related]
10. Licochalcone A suppresses hexokinase 2-mediated tumor glycolysis in gastric cancer via downregulation of the Akt signaling pathway.
Wu J; Zhang X; Wang Y; Sun Q; Chen M; Liu S; Zou X
Oncol Rep; 2018 Mar; 39(3):1181-1190. PubMed ID: 29286170
[TBL] [Abstract][Full Text] [Related]
11. A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancer.
Ma Y; Yu C; Mohamed EM; Shao H; Wang L; Sundaresan G; Zweit J; Idowu M; Fang X
Oncogene; 2016 Nov; 35(47):6132-6142. PubMed ID: 27132509
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-induced oxidative stress promotes therapy resistance via upregulation of heme oxygenase-1 in multiple myeloma.
Abe K; Ikeda S; Nara M; Kitadate A; Tagawa H; Takahashi N
Cancer Med; 2023 Apr; 12(8):9709-9722. PubMed ID: 36775962
[TBL] [Abstract][Full Text] [Related]
13. [Identification of hypoxia-specific therapeutic targets in multiple myeloma].
Ikeda S
Rinsho Ketsueki; 2021; 62(4):305-313. PubMed ID: 33967156
[TBL] [Abstract][Full Text] [Related]
14. The miR-125a/HK2 axis regulates cancer cell energy metabolism reprogramming in hepatocellular carcinoma.
Jin F; Wang Y; Zhu Y; Li S; Liu Y; Chen C; Wang X; Zen K; Li L
Sci Rep; 2017 Jun; 7(1):3089. PubMed ID: 28596599
[TBL] [Abstract][Full Text] [Related]
15. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma.
Kim W; Yoon JH; Jeong JM; Cheon GJ; Lee TS; Yang JI; Park SC; Lee HS
Mol Cancer Ther; 2007 Sep; 6(9):2554-62. PubMed ID: 17876052
[TBL] [Abstract][Full Text] [Related]
17. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
He R; Liu H
Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.
Ikeda S; Kitadate A; Abe F; Saitoh H; Michishita Y; Hatano Y; Kawabata Y; Kitabayashi A; Teshima K; Kume M; Takahashi N; Tagawa H
Cancer Sci; 2017 Apr; 108(4):641-652. PubMed ID: 28164410
[TBL] [Abstract][Full Text] [Related]
19. A Tumor Agnostic Therapeutic Strategy for Hexokinase 1-Null/Hexokinase 2-Positive Cancers.
Xu S; Herschman HR
Cancer Res; 2019 Dec; 79(23):5907-5914. PubMed ID: 31434645
[TBL] [Abstract][Full Text] [Related]
20. Role of endoplasmic reticulum stress in apoptosis induced by HK2 inhibitor and its potential as a new drug combination strategy.
Zhong J; Lu S; Jia X; Li Q; Liu L; Xie P; Wang G; Lu M; Gao W; Zhao T; Wang Q; Su W; Li N
Cell Stress Chaperones; 2022 May; 27(3):273-283. PubMed ID: 35355227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
